Kayne Anderson Rudnick Investment Management LLC Cogent Biosciences, Inc. Transaction History

Kayne Anderson Rudnick Investment Management LLC

$43.7 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	SELL	$3.92 - $9.73 $544 - $1,352	-139 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.31 - $8.7 $738 - $1,209	139 New	139 $1,000

Others Institutions Holding COGT

# of Institutions

172

Shares Held

113M

Call Options Held

56.7K

Put Options Held

40.4K

Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

10.5M
Shares

$82.5 Million
0.31% of portfolio
Kynam Capital Management, LP Princeton, NJ

9.24M
Shares

$72.8 Million
8.19% of portfolio
Commodore Capital LP New York, NY

7.54M
Shares

$59.4 Million
6.92% of portfolio
Black Rock Inc. New York, NY

7.29M
Shares

$57.4 Million
0.0% of portfolio
Tcg Crossover Management, LLC Palo Alto, CA

6.96M
Shares

$54.9 Million
9.76% of portfolio

View Full List

About Cogent Biosciences, Inc.

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $518M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

More about COGT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kayne Anderson Rudnick Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kayne Anderson Rudnick Investment Management LLC with notifications on news.

Account